Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02157714 | Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease | PHASE1 | COMPLETED | 64 | — | — | Jun 1, 2014 | - | Oct 21, 2016 | 8 | United States |
| NCT02095171 | Single Ascending Dose Study of PRX002 in Healthy Subjects | PHASE1 | COMPLETED | 40 | — | — | Mar 1, 2014 | - | Feb 10, 2015 | 1 | United States |
maximum concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| PRX002 | EXPERIMENTAL | PRX002 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PRX002 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Idiopathic Parkinson's disease, Hoehn and Yahr 1-3 * Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs * Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception * Male subjects and their partners of childbearin...